Apolipoprotein Inhibitor

Apolipoprotein Inhibitors (27):

Cat. No.	Product Name	Effect	Purity

HY-122208

SGA360	Inhibitor	99.93%
SGA360 suppress inflammatory SAA1 signaling in an AHR-dependent manner through a mechanism that does not require AHR binding to its cognate response element (partial antagonist).

HY-W011824

2′-O-Methyluridine	Inhibitor	99.92%
2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer.

HY-108764B

Mipomersen sodium scrambled negative control	Inhibitor	98.20%
Mipomersen sodium scrambled negative control is the sequence scrambled negative control of Mipomersen sodium.

HY-132820

Inaxaplin	Inhibitor	99.44%
Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.

HY-147425A

Zerlasiran sodium	Inhibitor
Zerlasiran (SLN360) sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.

HY-143200

OSBPL7-IN-1	Inhibitor	99.84%
OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression.

HY-141885

APOL1-IN-1	Inhibitor	99.85%
APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD).

HY-177653A

Opemalirsen sodium	Inhibitor
Opemalirsen sodium is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.

HY-147425

Zerlasiran	Inhibitor
Zerlasiran (SLN360) is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.

HY-W011824S

2′-O-Methyluridine-d₃	Inhibitor	99.19%
2′-O-Methyluridine-d₃ is deuterium labeled 2′-O-Methyluridine (HY-W011824).2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer.

HY-W011824R

2′-O-Methyluridine (Standard)	Inhibitor
2′-O-Methyluridine (Standard) is the analytical standard of 2′-O-Methyluridine (HY-W001824). This product is intended for research and analytical applications. 2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer.

HY-176196

APOL1-IN-3	Inhibitor
APOL1-IN-3 (Compound 1) is an APOL1 inhibitor. APOL1-IN-3 can be used in the research of kidney diseases.

HY-147425D

FAM labled Zerlasiran sodium	Inhibitor
FAM labled Zerlasiran sodium is a FAM labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.

HY-18778B

Obicetrapib potassium	Inhibitor
Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).

HY-169932

APOL1-IN-2	Inhibitor
APOL1-IN-2 (Compound 467) is the inhibitor for Apolipoprotein 1 (APOL1). APOL1-IN-2 reduces the APOL1 G2/G1 induced cell death in HEK293 with EC₅₀ of 4.74 nM and 14.3 nM. APOL1-IN-2 reduces the APOL1 G2/G1/G0 induced death of trypanosomes with EC₅₀ of 2.24, 6.03 and 3.72 nM, respectively.

HY-127055

Tiadenol	Inhibitor
Tiadenol is an absorbable hypolipidemic agent. Tiadenol can effectively reduce triglycerides and decrease the level of apolipoprotein E in very low-density lipoproteins in hyperlipoproteinemia. Tiadenol causes hepatomegaly in rats and affects their hepatic lipid levels, cholesterol synthesis and absorption at high doses. Tiadenol can be used in the research of endocrine and metabolic diseases such as hyperlipidemia.

HY-165061

5(Z),11(Z),14(Z)-Eicosatrienoic acid	Inhibitor
5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.

HY-177653

Opemalirsen	Inhibitor
Opemalirsen is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.

HY-177653B

Opemalirsen sodium scrambled negative control	Inhibitor
Opemalirsen sodium scrambled negative control is the sequence scrambled negative control of Opemalirsen sodium.

HY-171464A

Lp(a)-IN-5 hydrochloride	Inhibitor	99.70%
Lp(a)-IN-5 (Compound A) hydrochloride is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 hydrochloride inhibits the assembly of Apo(a) and ApoB proteins with an IC₅₀ value of 0.41 nM. Lp(a)-IN-5 hydrochloride is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases.

Name
Email *

	Sorry, but the email address you supplied was invalid.